Author: Jacques Santucci

[ad_1] In a significant development, the U.S. Department of Health and Human Services (HHS) officially recommended on August, 30, 2023, that the U.S. Drug Enforcement Agency (DEA) reclassify marijuana from a Schedule I to Schedule III drug under the Controlled Substances Act. This recommendation follows President Biden’s directive last year to expedite a review of marijuana’s federal scheduling. The historic recommendation by a top federal health agency aligns with the growing momentum for cannabis reform in the United States, as first reported by Bloomberg News. Now, the decision on reclassification lies in the hands of the DEA. However, the conflicting landscape…